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Abstract We have isolated a cDNA (bv7-3) encoding a member
of the Na+,Cl^-dependent transporter family and its short
splicing variant (bv7-3s) by screening a bovine retina cDNA
library. Sequence analysis revealed that bv7-3 encodes a protein
of 729 amino acids and is a bovine homologue of the rat orphan
transporter v7-3-2. bv7-3s contains 265 amino acids, sharing 252
N-terminal amino acids with bv7-3. Both mRNAs for bv7-3 and
bv7-3s were detected in nervous system by Northern blot
analysis. In immunofluorescence analysis in transfected HEK
293T cells, myc-tagged bv7-3 was mainly detected on the plasma
membrane, whereas myc-tagged bv7-3s showed a pattern of
intracellular membrane staining.
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1. Introduction
Cloning of the transporter for Q-aminobutyric acid [1] and
norepinephrine [2] allowed the subsequent isolation of a num-
ber of cDNAs encoding homologous Na,Cl3-dependent
transporters, which has given great insight into the structural
and pharmacological mechanisms of transporters [3^5]. Re-
cently, several splicing variants of transporters have been
cloned, which indicated the occurrence of splicing in trans-
porter genes and regulation of mRNA expression. Glycine
transporter 1 (GlyT1) and glycine transporter 2 (GLYT2)
have several transporter variants (GlyT1a, GlyT1b, GlyT1c,
GLYT2a and GLYT2b) which di¡er only in their N-terminal
region and have similar transport a⁄nity for glycine. Variants
of GlyT1 show di¡erential tissue distribution of mRNAs in-
dicating the regulation of genetic elements responsible for the
tissue-speci¢c expression [6^12]. Serotonin transporter also
has variants at the 5P non-coding region that cause di¡erential
expression of mRNA [13^16]. Recently, a variant of the bo-
vine noradrenaline transporter with a di¡erent C-terminal cy-
toplasmic-facing region (18 amino acids) and 3P untranslated
region was isolated [17]. It was revealed that the C-terminal
region is important for correct targeting to the membrane and
then functional expression. With the Na,K,OH3-dependent
transporter family, Utsunomiya-Tate et al. described the rat
liver glutamate transporter (GLT1) which has di¡erent 5P ends
determining the tissue speci¢city of mRNA expression, and
showed that co-expression of both GLT1 with di¡erent 3P ends
results in an increase in Vmax of transport without a change in
Km [18]. Recently, Mayer et al. described two alternatively
spliced transcripts of the human glutamate transporter
EAAT2 (GLT1) that resulted from exon skipping or usage
of internal splice sites though details as to their function
and distribution have yet to be reported [19]. Thus, there
have been many studies concerning a wide variety of functions
of splicing variants of transporters.
Here we report a novel transporter termed bv7-3 and its
splicing variant bv7-3s. They share an N-terminal region
with four putative transmembrane domains. Di¡erential sub-
cellular localization of these clones was also shown.
2. Materials and methods
2.1. Screening and sequencing
The oligonucleotide probe (5P-TAGGGGATCAGGAAG(A/G)C-
ACCTCCGCCGTTCTTGTAGCACAGGTAGGGGAAGCGCCA-
CACGTT-3P) designed from TM1^TM2 of the Na,Cl3-dependent
transporter family was synthesized and 5P end-labeled with 32P. After
screening a bovine retina VZAP cDNA library, the inserts were ex-
cised from the positive phages with R408 helper phage and sequenced
by the dideoxy chain termination method as described [20^22]. Both
strands were sequenced.
2.2. Northern blot analysis
Poly(A) RNA (10 Wg) was extracted from retina, cerebral cortex,
cerebellum and liver of bovine using the Fast Track mRNA Isolation
kit (Invitrogen). The cDNA region speci¢c for bv7-3s (corresponding
to nucleotides 776^1193) and bv7-3 (1315^3229) and the common
region of both cDNAs (corresponding to nucleotides 1^378 of bv7-
3s) were labeled with 32P by random priming (105 cpm/ml). Northern
blot analysis using each cDNA probe was performed as described [20].
2.3. Immuno£uorescence analysis of HEK 293T cells transfected with
myc-tagged bv7-3 and myc-tagged bv7-3s
bv7-3 or bv7-3s was subcloned in the mammalian expression vector
pCAGGS [23]. The sequence of the c-myc epitope tag EQKLI-
SEEDLN was inserted just before the stop (TAG) codon in bv7-3
cDNA and in bv7-3s cDNA by PCR ampli¢cation. The PCR product
was digested with NheI-EcoRI for bv7-3 and EcoRI-EcoRI for bv7-3s,
and ligated into similarly digested pCAGGS-bv7-3 and pCAGGS-
bv7-3s respectively.
For transient transfections, HEK 293T cells were grown on cham-
ber slides (LAB-TEK) in Dulbecco’s minimum essential medium
(DMEM; Nikken Bio Medical Laboratory) supplemented with 10%
fetal bovine serum at 37‡C in a CO2 incubator. The cells were trans-
fected by Lipofectamine (Gibco BRL) with 0.25 Wg of the expression
plasmid myc-tagged bv7-3/pCAGGS or myc-tagged bv7-3s/pCAGGS
and left for 3 days in the CO2 incubator.
For immuno£uorescence experiments, the transfected cells were
¢xed with 4% paraformaldehyde and 0.21% picric acid in 0.1 M
phosphate-bu¡ered saline (PBS) for 1 h. These cells were stained by
immunocytochemistry using anti-myc 9E10 antibodies (ATCC; 1:3)
and anti-mouse IgG (Jackson; 1:500) as described in [24]. Immu-
no£uorescence was visualized with a photomicroscope Optiphot
(Nikon).
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3. Results
3.1. Cloning
We isolated 14 positive clones from a bovine retina cDNA
library, using a 62-mer oligonucleotide probe originated from
the Na,Cl3-dependent transporter gene family. Sequence
analysis revealed that seven independent clones shared identi-
cal nucleotide sequences. These seven clones were divided into
two groups according to their length: those with 12 trans-
membrane domains (bv7-3) and those with only four trans-
membrane domains (bv7-3s, bv7-3s2, bv7-3s3). The nucleotide
sequence data of bv7-3, bv7-3s, bv7-3s2 and bv7-3s3 have
been submitted to the DDBJ/EMBL/GenBank nucleotide se-
quence databases with the accession numbers AB02854,
AB02855, AB02856 and AB02857, respectively.
bv7-3 displayed 90.4% amino acid identity to rat orphan
transporter v7-3-2 which was cloned from a rat midbrain
cDNA library and belongs to the Na,Cl3-dependent trans-
porter family [20]. The initiating methionine was proposed in
comparison with another orphan transporter NTT4/rXT1
[25,26], since the sequence of the 5P seven amino acids
(MPKNSKV) was the same as that in NTT4. bv7-3 was
3217 bp long with an open reading frame of 2187 bp which
could encode a protein of 729 amino acids with a calculated
molecular mass of 82 kDa. The Kyte-Doolittle hydrophobic-
ity pro¢le [27] suggested the presence of 12 stretches of hydro-
phobic residues that represent potential transmembrane do-
mains as in other transporters. Potential sites for Asn-linked
glycosylation were located in the second, third and fourth
extracellular loops, which were di¡erent from other orphan
transporters including v-7-3-2 (Fig. 1a,b).
The shorter cDNAs, bv7-3s, bv7-3s2 and bv7-3s3, are quite
similar, although not identical since they had di¡erent-length
5P and 3P non-coding regions. They encoded an identical pro-
tein containing 265 amino acid residues. The N-terminal 252
amino acids of bv7-3s were the same as those of bv7-3. The
short variants contained only four putative transmembrane
domains, while bv7-3 consists of 12 putative transmembrane
domains (Fig. 1b,c). We selected bv7-3s for further analyses as
a short variant of the transporter among bv7-3s, bv7-3s2 and
bv7-3s3.
3.2. Northern blot analysis
To determine whether the short variants actually exist in
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Fig. 1. Nucleotide and deduced amino acid sequences of bv7-3s
cDNA (a), and schematic representation of bv7-3 (b) and bv7-3s (c)
showing proposed orientation in the plasma membrane. a: The cod-
ing region is numbered starting from the putative translation initia-
tion codon. Putative transmembrane regions are marked by solid
bars. N-Glycosylation sites are marked with asterisks. The region
common to bv7-3 is boxed. b,c: bv7-3 and bv7-3s share 252 N-ter-
minal amino acids as represented by the darkened line. bv7-3 con-
sists of 12 putative transmembrane domains, like other Na,Cl3-de-
pendent neurotransmitter transporters, while bv7-3s contains only
four such domains.
Fig. 2. Northern blot analysis using probes speci¢c for bv7-3s (left)
and bv7-3 (middle) and common to both (right). Expression of
mRNAs for bv7-3s and bv7-3 was detected in retina, cerebrum, and
cerebellum, but not in liver with a size of 2.0 kb and 4.4 kb respec-
tively (left and middle). Control hybridization of each blot with the
GAPDH probe is shown underneath. mRNA for bv7-3s was rela-
tively faint compared to that of bv7-3 (right).
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vivo, we investigated mRNA expression of bv7-3 and bv7-3s
by Northern blot analysis. Using cDNA probes speci¢c for
bv7-3, we detected bands in retina, cerebral cortex, and cer-
ebellum, but not in liver, with a size of 4.4 kb. With the use of
a cDNA probe speci¢c for bv7-3s, transcripts of bv7-3s were
detected in the same tissues as bv7-3 with a size of 2.0 kb (Fig.
2). Then, for quantitative estimation, we performed Northern
blot analysis using a cDNA probe common to bv7-3s and
bv7-3, and found that the detected band for bv7-3s was rela-
tively faint compared with that of bv7-3.
3.3. Immuno£uorescence analysis
The substrates of bv7-3 have yet to be determined. The
proteins of the members of the Na,Cl3-dependent transport-
er family are located in the plasma membrane where they
transport substrate from the extracellular into the intracellular
space. To con¢rm that bv7-3 is expressed at the cell surface to
take up the substrates, and to investigate the role of the short
variant bv7-3s, we determined the subcellular localization of
their protein in HEK 293T cells transiently transfected with
myc-tagged bv7-3s and myc-tagged bv7-3 by immuno£uores-
cence microscopy. bv7-3 was found on the plasma membrane
in the myc-tagged bv7-3-transfected cells. Interestingly, myc-
tagged bv7-3s showed a pattern of intracellular membrane
staining (Fig. 3).
4. Discussion
We cloned a novel type of splicing variant of transporter
(bv7-3s) with only four putative transmembrane domains. We
determined that these mRNAs are spliced from a single gene
by Southern blot analysis (data not shown). bv7-3s has the
nucleotides GT [28], the 5P consensus splice site for splicing
just after the common region with bv7-3, although the se-
quence around AAA/GTTAGT was not completely the
same as the consensus donor sequence (C/A)AG/GURAGU
(the intron-exon boundary is denoted by the vertical line)
(Fig. 1b) [29]. This result indicates that bv7-3s arises when
the pre-RNA for this transporter gene is not spliced but
cleaved and polyadenylated at internal poly(A) addition sites
in the same way as reported for the secreted immunoglobulin
W heavy chain (IgWs) [30,31]. Otherwise, bv7-3s may be pro-
duced via splicing with exons di¡erent from those of bv7-3
and using the associated internal polyadenylation sites, as
reported for calcitonin/CGRP [32]. The genomic sequence
will unveil details of the construction of exons.
The result that the mRNA expression of bv7-3s was rela-
tively faint compared with that of bv7-3 was also con¢rmed
by reverse transcription PCR (data not shown). This could be
due to (1) splicing regulation; splicing for the short variants
occurs at a low frequency, or it is amenable to regulation by
environmental signals, or (2) instability of the short variants
with di¡erent 3P non-coding regions.
Immuno£uorescence analysis revealed that myc-tagged bv7-
3s localized in the intracellular membrane whereas myc-tagged
bv7-3 was detected mainly in the cell surface in HEK 293T
cells. Turner et al. demonstrated the COOH-terminal is im-
portant for cellular sorting of the sodium-dependent glucose
cotransporter [33]. Perego et al. showed that on deletion of the
last 49 COOH-terminal amino acids, the betaine transporter
failed to reach the basolateral cell surface resulting in loss of
transport activity at the cell surface [34]. Olivares also showed
that deletion of more than 34 amino acids of the carboxy-
terminus of GlyT1 produced a progressive decrease in trans-
port activity and that those carriers were no longer found in
the membrane [24]. These ¢ndings suggest that the carboxy-
terminus of bv7-3 could be involved in the membrane inser-
tion process and that bv7-3s, by deletion of almost half the
carboxy-terminus of bv7-3, could no longer reach the plasma
membrane. The protein encoded by bv7-3s seems not to have
transporter activity at the cell surface but to be a by-product
of posttranscriptional regulation of bv7-3 or to have certain
functions at the intracellular membrane.
Whether the splicing of the short variant a¡ects the trans-
port activity remains unknown since we have not identi¢ed
the substrate of bv7-3 [20,25,26,35,36]. In previous reports
however, short transporter variants were detected by North-
ern blot analysis [10,35^37] suggesting that short splicing var-
iants are common and a¡ect the regulation of transporter
activity at the posttranscriptional level. And the posttranscrip-
tional regulation may be important for the stage of disease, as
indicated in a recent report that sporadic amyotrophic lateral
sclerosis patients have multiple abnormal EAAT2 variants
caused by intron retention and exon skipping which result
in loss of EAAT2 protein activity [38].
In conclusion, in the present study, we cloned novel splicing
variants of transporter, with the following traits. (1) They
share an N-terminal region with four putative transmembrane
domains and the shorter bv7-3s ends with 13 di¡erent amino
acids and a non-coding 3P region. (2) Their mRNAs are
present in the same tissue. (3) bv7-3s is localized in the intra-
cellular membrane, bv7-3 mainly at the cell surface. The func-
FEBS 21472 1-2-99
Fig. 3. Immuno£uorescence analysis of the cellular distribution of
myc-tag bv7-3 (a) and myc-tag bv7-3s (b) in transiently transfected
HEK293T cells. Myc-tagged bv7-3 was found at the cell surface,
whereas myc-tagged bv7-3s was detected in the intracellular mem-
brane. Magni¢cation, U180.
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tional role of this short-form transporter remains to be eluci-
dated. The results of our study are expected to o¡er insights
into the molecular mechanism of splicing of transporters.
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